Your browser doesn't support javascript.
loading
Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries.
Logroscino, Giancarlo; Piccininni, Marco; Graff, Caroline; Hardiman, Orla; Ludolph, Albert C; Moreno, Fermin; Otto, Markus; Remes, Anne M; Rowe, James B; Seelaar, Harro; Solje, Eino; Stefanova, Elka; Traykov, Latchezar; Jelic, Vesna; Rydell, Melissa Taheri; Pender, Niall; Anderl-Straub, Sarah; Barandiaran, Myriam; Gabilondo, Alazne; Krüger, Johanna; Murley, Alexander G; Rittman, Timothy; van der Ende, Emma L; van Swieten, John C; Hartikainen, Päivi; Stojmenovic, Gorana Mandic; Mehrabian, Shima; Benussi, Luisa; Alberici, Antonella; Dell'Abate, Maria Teresa; Zecca, Chiara; Borroni, Barbara.
Afiliação
  • Logroscino G; Center for Neurodegenerative Diseases and the Aging Brain, University of Bari-Aldo Moro, Bari at Pia Fondazione Cardinale Giovanni Panico, Tricase, Lecce, Italy.
  • Piccininni M; Institute of Public Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Graff C; Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Hardiman O; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
  • Ludolph AC; Unit for Hereditary Dementia, Theme Aging, Karolinska University Hospital-Solna, Stockholm, Sweden.
  • Moreno F; Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
  • Otto M; Department of Neurology, Beaumont Hospital, Dublin, Ireland.
  • Remes AM; Department of Neurology, University Hospital Ulm, Ulm, Germany.
  • Rowe JB; Deutsches Zentrum für Neurodegenerative Erkrankungen, Ulm, Germany.
  • Seelaar H; Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.
  • Solje E; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain.
  • Stefanova E; Department of Neurology, University Hospital Ulm, Ulm, Germany.
  • Traykov L; Department of Neurology, Martin Luther University, University Hospital, Halle (Saale), Germany.
  • Jelic V; Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.
  • Rydell MT; Medical Research Center, Oulu University Hospital, Oulu, Finland.
  • Pender N; Clinical Neurosciences, University of Helsinki, Helsinki, Finland.
  • Anderl-Straub S; Department of Clinical Neurosciences, MRC Cognition and Brain Sciences Unit, and Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, United Kingdom.
  • Barandiaran M; Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Gabilondo A; Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland.
  • Krüger J; NeuroCenter, Neurology, Kuopio University Hospital, Kuopio, Finland.
  • Murley AG; Faculty of Medicine, Neurology Clinic, University Clinical Center, University of Belgrade, Serbia.
  • Rittman T; Alexandrovska University Hospital, Department of Neurology, Medical University Sofia, Sofia, Bulgaria.
  • van der Ende EL; Theme Inflammation and Aging, Medical Unit Aging Brain, Karolinska University Hospital Huddinge, Solna, Sweden.
  • van Swieten JC; Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
  • Hartikainen P; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
  • Stojmenovic GM; Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
  • Mehrabian S; Department of Neurology, Beaumont Hospital, Dublin, Ireland.
  • Benussi L; Department of Neurology, University Hospital Ulm, Ulm, Germany.
  • Alberici A; Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.
  • Dell'Abate MT; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain.
  • Zecca C; Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.
  • Borroni B; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain.
JAMA Neurol ; 80(3): 279-286, 2023 03 01.
Article em En | MEDLINE | ID: mdl-36716024
ABSTRACT
Importance Diagnostic incidence data for syndromes associated with frontotemporal lobar degeneration (FTLD) in multinational studies are urgent in light of upcoming therapeutic approaches.

Objective:

To assess the incidence of FTLD across Europe. Design, Setting, and

Participants:

The Frontotemporal Dementia Incidence European Research Study (FRONTIERS) was a retrospective cohort study conducted from June 1, 2018, to May 31, 2019, using a population-based registry from 13 tertiary FTLD research clinics from the UK, the Netherlands, Finland, Sweden, Spain, Bulgaria, Serbia, Germany, and Italy and including all new FTLD-associated cases during the study period, with a combined catchment population of 11 023 643 person-years. Included patients fulfilled criteria for the behavioral variant of frontotemporal dementia (BVFTD), the nonfluent variant or semantic variant of primary progressive aphasia (PPA), unspecified PPA, progressive supranuclear palsy, corticobasal syndrome, or frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS). Data were analyzed from July 19 to December 7, 2021. Main Outcomes and

Measures:

Random-intercept Poisson models were used to obtain estimates of the European FTLD incidence rate accounting for geographic heterogeneity.

Results:

Based on 267 identified cases (mean [SD] patient age, 66.70 [9.02] years; 156 males [58.43%]), the estimated annual incidence rate for FTLD in Europe was 2.36 cases per 100 000 person-years (95% CI, 1.59-3.51 cases per 100 000 person-years). There was a progressive increase in FTLD incidence across age, reaching its peak at the age of 71 years, with 13.09 cases per 100 000 person-years (95% CI, 8.46-18.93 cases per 100 000 person-years) among men and 7.88 cases per 100 000 person-years (95% CI, 5.39-11.60 cases per 100 000 person-years) among women. Overall, the incidence was higher among men (2.84 cases per 100 000 person-years; 95% CI, 1.88-4.27 cases per 100 000 person-years) than among women (1.91 cases per 100 000 person-years; 95% CI, 1.26-2.91 cases per 100 000 person-years). BVFTD was the most common phenotype (107 cases [40.07%]), followed by PPA (76 [28.46%]) and extrapyramidal phenotypes (69 [25.84%]). FTD-ALS was the rarest phenotype (15 cases [5.62%]). A total of 95 patients with FTLD (35.58%) had a family history of dementia. The estimated number of new FTLD cases per year in Europe was 12 057. Conclusions and Relevance The findings suggest that FTLD-associated syndromes are more common than previously recognized, and diagnosis should be considered at any age. Improved knowledge of FTLD incidence may contribute to appropriate health and social care planning and in the design of future clinical trials.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Degeneração Lobar Frontotemporal / Demência Frontotemporal / Esclerose Lateral Amiotrófica Tipo de estudo: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: JAMA Neurol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Degeneração Lobar Frontotemporal / Demência Frontotemporal / Esclerose Lateral Amiotrófica Tipo de estudo: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: JAMA Neurol Ano de publicação: 2023 Tipo de documento: Article